C4 Therapeutics, Inc. (CCCC) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Join SI Premium – FREE
C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $6.64 million versus the consensus estimate of $8.2 million.
For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westport Fuel Systems (WPRT) Misses Q2 EPS by 64c
- Canterbury Park (CPHC) Misses Q2 EPS by 3c
- Optex Systems Holdings, Inc. (OPXS) Misses Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
